NEW YORK (GenomeWeb) – Invitae announced today that it has completed its acquisition of CombiMatrix.

With the closing of the deal, Invitae issued approximately $21.2 million in shares of its own common stock, about 2.7 million shares, to former CombiMatrix shareholders. Combined with the approximately 1.7 million shares of Invitae common stock underlying CombiMatrix Series F warrants assumed in the acquisition, the transaction has a total enterprise value of approximately $34.9 million, Invitae said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.